 |
| |
 |
| |
14-17 November 2011
The Network Annual conference in Prague, Czech Republic
Workshop, PhD Course (2011) |
|
|
|
|
 |
 |
The importance of neutralising antibodies in protection against HIV infection and disease can be inferred from other viral infections even if the mechanism of protection remains to be elucidated. Numerous in vitro neutralisation assays have been developed, each one with different variables and endpoints. NeutNet, a network of independent laboratories from all over the world, started activities in 2004 aiming to compare methods for the measurements of HIV-1 neutralising antibodies for use in vaccine research and human clinical trials of candidate AIDS vaccines. NeutNet has organised an initial study with the most frequently used neutralisation techniques and a panel of well-characterised and common reagents. The study was recently completed and its results published in PlosOne. These results served as the basis for a subsequent study with polyclonal serologic reagents to elucidate the prerequisites of accurate and reproducible measurement of HIV-1 functional antibodies. The results of NeutNet will help HIV vaccine research and clinical trials making it possible to compare all vaccine efforts throughout Europe and beyond.
|
|
